We retrospectively reviewed the charts of all of our patients with a history of partial seizures, with and without secondarily generalisation, who received levetiracetam (LEV; Keppra ® ) for treatment of their seizures during the years 2000-2002. Forty-five patients were identified, 13 of whom began LEV as first line therapy. Eleven patients continued on LEV for at least 6 months; six of whom became seizure free and five had >50% reduction in their seizures. The remaining two patients discontinued LEV because of adverse effects. LEV monotherapy can be effective and well tolerated in adults with new onset seizures. A prospective, large, double-blind monotherapy study for newly diagnosed patients is needed to confirm this finding.
INTRODUCTION
Levetiracetam (LEV) is a novel antiepileptic drug (AED) that received FDA approval in November 1999 as adjunctive treatment for adults with partial onset seizures. Its effectiveness was established in three multicentre, well-controlled pivotal drug study trials [1] [2] [3] . In addition, LEV is well tolerated with a favourable pharmacokinetic profile that includes minimal protein binding, lack of hepatic metabolism and twice a day dosing 4 . These features and others make it ideal for use as monotherapy.
In a European multicentre placebo-controlled, responder-selected monotherapy study, conversion to LEV monotherapy was successful in patients with refractory partial epilepsy 3 . However, the effectiveness of LEV as a single agent in newly diagnosed epilepsy patients is currently unknown. In this study, we wished to review our experience with LEV in newly diagnosed epilepsy patients.
METHODS
We retrospectively reviewed the charts of our patients who were diagnosed with epilepsy after having two unprovoked seizures during the years 2000-2002. All patients underwent a thorough workup that included MRI and EEG. We identified patients who received LEV as monotherapy or as adjunctive treatment. From this cohort of patients, we identified 13 patients with newly diagnosed epilepsy. Ten of these patients were never exposed to an AED, while three briefly received an AED (less than 2 weeks), but had to discontinue because of poor tolerance or side-effects (n = 3).
We reviewed patients' demographic data, diagnostic evaluation for epilepsy, seizure types and seizure frequency prior to and following initiation of LEV monotherapy. All patients had follow-up visits at regular intervals every 2 months, or at shorter intervals if medically necessary. No patients failed to follow-up while on LEV. All patients had their LEV dose titrated from a starting dose of 500 mg day −1 in two divided doses up to a maximum tolerated dose no greater than 5000 mg day −1 . For elderly patients, the dose was titrated up to 2000 mg day −1 or seizure freedom. We compared baseline seizure counts from the 2 months prior to initiation of LEV treatment to seizure counts at 6 months of follow-up after LEV was started and maintained as therapy. Seizure frequency was determined using a seizure diary completed by each patient or his or her caregivers, which is standard practice in our clinic. Adverse events (AEs) while on LEV were also noted at each clinic visit. This information was kept in a computerised data system that was maintained up-to-date by the co-author (CT).
RESULTS
We identified 13 female patients, ages 17-66 (mean 40.3), with a history of partial seizures with and without secondarily generalisation. (Although our clinic includes males and females, no males met the inclusion criteria for this study.) The duration of epilepsy ranged from 1 to 52 years (mean 5.4 years, median 2 years). One patient had undiagnosed seizures for 52 years prior to LEV treatment. Three of these patients had liver disease and consequently wished to avoid AEDs that required hepatic metabolism. The remaining nine patients chose to start LEV because of its favourable pharmacokinetic and side-effect profile. Five patients had an identifiable cause to their seizures; two secondary to head trauma, two secondary to stroke and one secondary to cortical dysplasia. Characteristics and demographics of our group of patients are summarised in Table 1. Of the 13 patients, eleven (84%) continued on LEV monotherapy for at least 6 months. Two patients discontinued therapy within 2 weeks after LEV was started at dosages less than 500 mg day −1 because of side-effects (irritability). Of the 11 patients who were maintained on LEV as first line therapy for at least 6 months, 6 became seizure free and 5 patients had >50% reduction in their seizures (Fig. 1) .
Three patients reported being nervous (irritable) within 2 weeks after starting on LEV as a single agent on 500 mg day −1 of LEV. Two patients discontinued LEV, while the third patient was able to continue on LEV when her complaints decreased after the first month of therapy. Another patient reported being dizzy within days after starting LEV but was able to continue on LEV. No other major AEs were reported. 
DISCUSSION
This study suggests that LEV monotherapy can be effective in treating newly diagnosed epilepsy patients. Forty-six percent of our patients became seizure free after starting LEV and 38% had more than a 50% reduction of their seizures. This finding is consistent with earlier studies using old and new generation AEDs 5, 6 . Still, 15% (2 of 13) of these patients discontinued LEV because of irritability occurring within the first few days of LEV at small doses (500 mg day −1 in two divided doses). To our knowledge, this is the first reported study using LEV monotherapy for newly diagnosed epilepsy patients. Previous work at this centre, as well as the work of others, has demonstrated successful conversion to monotherapy in patients with difficult to control and refractory epilepsy 3, 7 . However, the effectiveness of LEV in newly diagnosed cases was not studied.
These results are important because AEDs approved for adjunctive therapy may not be effective as monotherapy 8 . For example, although gabapentin and tiagabine demonstrated effectiveness as add-on treatments in refractory partial seizures [9] [10] [11] , monotherapy trials in newly diagnosed patients failed to show efficacy. These findings would suggest that not all AEDs approved as an add-on therapy will be effective as monotherapy for newly diagnosed patients and emphasises the need for monotherapy trials. It is also not clear if any of the new AEDs would be effective only as monotherapy for difficult to control and refractory epilepsy patients, but may not show similar efficacy for the newly diagnosed patients, as has been previously shown in one study utilising Vigabtrin 12 . The small number of patients studied, as well as the retrospective nature of this study and the short term of follow-up, may not allow us to make firm conclusions. However, our experience suggests that LEV can be effective as monotherapy in newly diagnosed epilepsy patients. Although all of our patients were female, there is no apparent reason why these results would not also apply to males. A larger study including both sexes with an extended follow-up period is planned.
Two of our patients experienced irritability that required discontinuation of the drug. Behavioural symptoms associated with LEV have been observed in 13.3% of patients in placebo-controlled epilepsy trials and to a lesser extent in non-epilepsy trials utilising LEV monotherapy 13 . Reports of behavioural problems during LEV treatment were associated in patients with a pre-study history of psychiatric problems. All three patients who reported irritability in our study had this problem within the first 2 weeks of LEV therapy at smaller than the recommended starting dosages. Only two of our cohort of patients had a history of depression prior to starting LEV treatment, both reported irritability. Our observations, in agreement with the others, suggest that these AEs do not appear to be dose related 13, 14 . What makes a minority of patients susceptible to LEV-related behavioural side-effects remains to be determined.
In summary, we found that LEV can be effective as monotherapy in patients with newly diagnosed epilepsy. In addition, it is very well tolerated with only a small number of patients discontinuing the drug due to side-effects. A larger double-blind monotherapy study for newly diagnosed patients is needed to confirm our findings.
